Sana Biotechnology (SANA) Non-Current Assets (2020 - 2026)

Sana Biotechnology has reported Non-Current Assets for 7 years, with the latest figure at $261.9 million in Q1 2026.

• Quarterly Non-Current Assets fell 21.29% year-over-year to $261.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (down 21.38% YoY) and the FY2025 annual result came in at $268.2 million, down 21.16% from the prior year.
• Non-Current Assets slipped to $261.9 million in Q1 2026 per SANA's latest filing, from $268.2 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $524.4 million in Q1 2022 and troughed at $261.9 million in Q1 2026.
• A 5-year average of $355.7 million and a median of $351.9 million in 2023 frame the typical range for Non-Current Assets.
• The widest YoY moves for Non-Current Assets: up 55.61% in 2022, down 35.82% in 2022.
• Over 5 years, Non-Current Assets stood at $378.3 million in 2022, then decreased by 7.01% to $351.8 million in 2023, then decreased by 3.29% to $340.2 million in 2024, then fell by 21.16% to $268.2 million in 2025, then decreased by 2.35% to $261.9 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $261.9 million, $268.2 million, and $273.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.